two administrations of an immunopotentiator , ok-432 or human interleukin-2 , prior to the subcutaneous inoculation of hcc-m cells , which was performed 24 h after the last administration , significantly inhibited the tumor development in terms of rate of tumor take and tumor size .
C0086418
human
C0021756
interleukin-2